Premium
Efficacy and safety of recombinant human interleukin‐11 in the treatment of acute leukaemia patients with chemotherapy‐induced thrombocytopenia: A systematic review and meta‐analysis
Author(s) -
Liu ZhiRong,
Wang Yaxuan,
Yan Jingxin,
Liu Junhong,
Chen Bing,
Zhang LuShun,
Cheng Li
Publication year - 2020
Publication title -
journal of evaluation in clinical practice
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.737
H-Index - 73
eISSN - 1365-2753
pISSN - 1356-1294
DOI - 10.1111/jep.13152
Subject(s) - medicine , meta analysis , adverse effect , cochrane library , observational study , randomized controlled trial , platelet , chemotherapy , interleukin 11 , platelet transfusion , interleukin , cytokine
Rationale, aims, and objectives Current meta‐analysis was conducted aiming to assess the efficacy and safety of recombinant human interleukin‐11 (rhIL‐11) in the treatment of acute leukaemia (AL) patients with chemotherapy‐induced thrombocytopenia (CIT). Methods We searched PubMed, Embase, Chinese National Knowledge Infrastructure database (CNKI), Cochrane Library, and Wan Fang Database on 4 July 2018. Results Ten randomized controlled trials (RCTs) and two observational studies were included, which involved 754 AL patients with CIT. Pooled analysis demonstrated that rhIL‐11 was beneficial on CIT: recovery time of platelet count to 50 × 10 9 / L [weight mean difference (WMD) = −4.19 days; 95% CI: −5.01, −3.37], recovery time of platelet count to 100 × 10 9 / L (WMD = −4.45 days; 95% CI: −4.85, −4.06), platelet transfusion volume (WMD = −6.14 U; 95% CI: −9.20, −3.09), and the rate of haemorrhage (RR = 0.46; 95% CI: 0.36 to 0.61). Most adverse events associated with rhIL‐11 were mild to moderate. Conclusion Our findings suggest that rhIL‐11 is effective and safe in the treatment of CIT in patients with AL.